Avita Medical price target raised to $25 from $22 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Avita Medical to $25 from $22 and keeps an Overweight rating on the shares. Avita Medical reported commercial revenue of $14.1M, representing year over year growth of 50%, the analyst tells investors in a research note. The firm is incrementally positive on the shares.